DALLAS, July 7, 2014 /PRNewswire/ -- Macrocyclics, Inc. (an AREVA Med company) announced today the launch of new offices located in China, Japan, South Korea, and France. The production laboratory remains based in Dallas, Texas, USA; however, Asian and French customers will now have a local contact for placing orders and obtaining technical information about all products and services available from Macrocyclics, and the ability to communicate in their own language as well as English.
To reach Macrocyclics in their new offices, please use the following:
Beijing, China Mrs. Carrie SONG +86-150-1146-1640 | Tokyo, Japan Mr. Sebastien PAES +81-90-2620-5448 |
Seoul, South Korea Mrs. Hye-Young PARK +82-2-551-01-65 | Limoges, France Mr. Remy DUREAU +33-6-46-42-45-65 |
Macrocyclics specializes in the manufacture of customized chelating agents used in nuclear medicine and medical imaging. We also offer custom-made cGMP products for use in clinical trials, bioconjugation services, and consulting services that will help our customers select the proper isotopes for their particular needs.
Please visit http://www.macrocyclics.com for detailed information.
MORE ABOUT MACROCYCLICS
Macrocyclics is the global leader in high performance chelating agent technologies for medicine since 1995. Our team at Macrocyclics is dedicated to providing clients with both established and innovative chelating agents and services to meet the challenges of molecular imaging and nuclear medicine. www.macrocyclics.com
MORE ABOUT AREVA MED
AREVA Med is an AREVA subsidiary specializing in the development of innovative therapies to fight cancer. AREVA Med has developed new processes for producing high purity lead-212 (212Pb), a rare metal that is currently at the heart of promising nuclear medicine research. In 2011, AREVA Med acquired Macrocyclics, the global leader in high performance chelating agent technology. AREVA Med is also associated with world-class scientific partners, such as the National Cancer Institute (NCI), the University of Alabama at Birmingham (UAB), and the French National Institute of Health and Medical Research (Inserm). In 2012, AREVA Med and Roche entered a strategic alliance to create novel advanced alpha radioimmunotherapy treatments to target and kill certain very aggressive types of cancer cells. For more information: www.arevamed.com or www.targetedtrials.com. @AREVAmed
Macrocyclics
Garry Kiefer
T: +1-972-250-2248
F: +1-972-250-2245
info@macrocyclics.com
AREVA Med
Alison Tise
T: +1-301-841-1673
F: +1-240-235-0966
alison.tise@areva.com
@AREVAmed
![[Poster] Analytical Performance Experimentation assessment of the miLab™ MAL Malaria system for the detection of Plasmodium falciparum in clinical samples in Lagos, Nigeria](https://mma.prnasia.com/media2/2395917/Poster__Analytical_Performance_Experimentation_assessment_of_the_miLab__MAL_Malaria_system_for_the_d.jpg?p=medium600)
